Skip to main content
STOK
NASDAQ Life Sciences

Stoke 10-Q: $358.8M Cash Into Early 2028, Q3 Loss Widens to $73.6M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$26.99
Mkt Cap
$1.749B
52W Low
$20.32
52W High
$40.22
52W Position info
33% above low
Off High info
33% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

STOK sits 33% above its 52-week low of $20.32.

Summary

Stoke's Q3 10-Q shows a $73.6 million quarterly loss and $358.8 million in cash and securities, enough to fund operations into early 2028, with $146.4 million already raised through its at-the-market program this year.


Key Events · Earnings and Guidance · STOK

  • Q3 Loss Widens to $73.6M

    Net loss was $73.6 million, or $1.08 per share, versus $38.3 million a year earlier, on revenue of $11.3 million.

  • Runway Into Early 2028

    Cash, cash equivalents and marketable securities totaled $358.8 million at September 30, 2026, which management says funds operations into early 2028.

  • Spending Climbs Sharply

    R&D rose $22.1 million to $59.8 million and SG&A rose $12.7 million to $28.7 million in the quarter, driven by zorevunersen costs and commercial readiness.

  • ATM Used Heavily, $200M Untapped

    4.6 million shares were sold for $146.4 million net proceeds through September 30, 2026; no shares have been sold under the August 2026 $200.0 million prospectus.


Analysis · STOK · Life Sciences

The quarterly filing confirms the loss trajectory behind the October 29 release and, more importantly, puts hard numbers on the balance sheet: $358.8 million in cash and securities funds operations into early 2028, past the expected Q3 2027 EMPEROR readout and the planned second-half 2027 NDA submission. Spending is climbing fast — R&D rose $22.1 million and SG&A $12.7 million year over year as the company builds commercial infrastructure — and the company has already pulled $146.4 million from its at-the-market program this year, leaving a fresh $200.0 million shelf unused. That combination means the runway is real but dependent on continued share sales if costs keep rising.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, STOK was trading at $26.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $20.32 to $40.22. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

STOK - Latest Insights

STOK
Oct 29, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $26.36
Real-time Price: $26.69 info
Change: +$0.330 (+1%) info
Market Cap: $1.746B info
STOK
Oct 21, 2026, 4:42 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.68
Real-time Price: $26.69 info
Change: +$1.01 (+4%) info
Market Cap: $1.746B info
STOK
Oct 05, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $25.62
Real-time Price: $26.69 info
Change: +$1.07 (+4%) info
Market Cap: $1.746B info
STOK
Sep 03, 2026, 7:30 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $29.99
Real-time Price: $26.69 info
Change: -$3.30 (-11%) info
Market Cap: $1.746B info
STOK
Aug 03, 2026, 5:04 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $27.95
Real-time Price: $26.69 info
Change: -$1.26 (-5%) info
Market Cap: $1.746B info